BEVERLY HILLS, Calif.--(EON: Enhanced Online News)--Life Stem Genetics, Inc. (OTCBB: LIFS), an emerging innovator in the advancement of Adult Stem Cell therapy, today announced that it has added Dr. Shirin Rostamkalaee, an expert on wound healing, bone grafting, and reconstructive surgery (broad areas with immense applications for Adult Stem Cell (“ASC”) therapies) to its newly expanded Executive Advisory Board. The addition of Dr. Rostamkalaee follows the recent appointments of Matthew Sullivan, COO of global health products company Asana International, and Shahab Bakhtyar, an independent medical business consultant with extensive global experience, to the company’s Executive Advisory Board.
“Dr. Rostamkalaee is a world expert in the field of reconstructive surgical methodologies, an area of medical science that is just beginning to uncover the immense potential of Adult Stem Cell therapies”
Established earlier this year, the Executive Advisory Board has become a cornerstone of Life Stem’s global stem-cell growth model. The company has been actively retaining medical experts and business leaders who can successfully guide the company’s expansion into key growth centers throughout Europe, Asia, North America and the Middle East.
Dr. Rostamkalaee received her medical degree from the University of Medical Sciences and Health Services. In addition to her vast experience in patient care overseas and in Canada, Dr. Rostamkalaee completed her medical thesis on usage of bone grafting in plastic and reconstructive surgeries, an emergent area in the field of Adult Stem Cell therapies.
“Dr. Rostamkalaee is a world expert in the field of reconstructive surgical methodologies, an area of medical science that is just beginning to uncover the immense potential of Adult Stem Cell therapies,” states Gloria Simov, President and CEO of Life Stem Genetics. “We look forward to working with Dr. Rostamkalaee to explore new methods of Adult Stem Cell treatment and are very fortunate to have her guidance as we expand our base of ASC clinics in the United States and internationally.”
About Life Stem Genetics
Life Stem Genetics (“LSG”) is a progressive healthcare company focused on Adult Stem Cell (ASC) healing therapies. For decades, stem cells have been utilized in the successful treatment of a variety of ailments. Today, advanced ASC therapies are being offered to patients as an efficient and painless alternative treatment for a wide range of ailments including, but not limited to, orthopedic injuries, neurological disorders such as Parkinson’s and Alzheimer’s, cancer, arthritis, diabetes, multiple sclerosis, as well as age management. Adult Stem Cell therapies and LSG’s proprietary techniques are experiencing some of the best results in the industry in helping to repair or reprogram damaged or diseased tissues and organs. Life Stem’s ASC specialist has performed thousands of stem cell treatments including some of the top names in PGA golf, NFL football, NBA basketball, and Major League Baseball. LSG will offer its proprietary treatments through a series of affiliate doctors and medical clinics with 60 affiliated clinics thus far. LSG’s mission is to develop a comprehensive approach to the treatment and maintenance of diseases while breaking free from the medical insurance maze by tapping into an affordable private-pay sector.
Contrarian Press, an established publisher, has been engaged by Life Stem Genetics to assist with identification of potential market participants who may be interested in learning more about the company and its securities. Updated disclaimer and disclosure information is available at the publisher's website and at the following link: http://www.contrarianwealthcoalition.com/guide/LIFS.pdf
For a copy of LIFS logo is available at: http://www.lifestemgenetics.com/wp-content/themes/LifeStemGenetics/images/life-stem-genetics-logo.png
This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995 that are not historical facts. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may”, “could”, “estimates”, "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology, and include discussions of strategy, and statements about industry trends and the Company's future performance, operations, and products. Such statements involve known and unknown risks, uncertainties and other factors that could cause the Company's actual results to differ materially from the results expressed or implied by such statements. Such risks and uncertainties include, without limitation, market acceptance of the Company's stem cell therapy treatment program; the Company's compliance with applicable statutes and regulations: the Company's reliance on third-party contractors to provide suitable treatment facilities; the Company's ability to expand its network of participating clinics and doctors; the Company's ability to develop an effective marketing strategy; the Company's ability to control and reduce advertising and marketing costs; the Company's ability to develop and increase awareness of its brand; the Company's ability to protect its trademarks; and the success of the Company's marketing focus to patients, doctors and clinics. For a discussion of these and other risks and uncertainties see "Risk Factors" and “Description of Business” in the Company's public filings with the SEC. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.